Bristol-Myers Squibb: all 2,184 studies

Page 21 of 22. Open to participants first (162), then studies with results posted, then the rest; newest registration first within each.

• A Study of BMS-663513 Administered in Combination With Chemotherapy to Subjects With Advanced Solid MalignanciesTerminatedNCT00351325Phase 1
• Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALLWithdrawnNCT00349518Phase 2/3
• Study of Recombinant Interleukin 21 in Combination With Rituxan for Non-Hodgkin's LymphomaCompletedNCT00347971Phase 1
• A Study of Abatacept in Japanese Patients With Active Rheumatoid Arthritis While Receiving MethotrexateCompletedNCT00345748Phase 2
• Phase II Study of Weekly Paclitaxel (BMS-181339)in Patients With Advanced or Recurrent Esophageal CancerCompletedNCT00344552Phase 2
• Study to Evaluate The Analgesic Efficacy and Safety of Intravenous Paracetamol in Subjects With Postoperative Pain After Total Hip ArthroplastyCompletedNCT00344045Phase 4
• A Phase II Trial Neoadjuvant Paclitaxel and Cisplatin in Patients With Locally Advanced Head and Neck CancerCompletedNCT00337532Phase 2/3
• Study of BMS-354825 in Subjects With CML Who Are Resistant to or Intolerant of Imatinib or Ph+All in JapanCompletedNCT00337454Phase 1/2
• A Phase I Study of BMS-275183 (Oral Taxane) Given on a Daily Schedule in Combination With Esomeprazole (Nexium) in Patients With Advanced CancerTerminatedNCT00332748Phase 1
• A Phase I Study of BMS-690514 in Patients With Advanced or Metastatic Solid TumorsCompletedNCT00329004Phase 1
• A Phase I Dose-Escalation Study of BMS-641988 in Patients With Castration-Resistant Prostate CancerCompletedNCT00326586Phase 1
• A Phase I Study of a Single Dose of Radio-labeled BMS-275183 in Patients With Advanced CancerTerminatedNCT00326131Phase 1
• A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous LeukemiaCompletedNCT00324220Phase 1/2
• A Phase I Study of MGCD0103 Given Twice Weekly in Patients With Leukemia or Myelodysplastic SyndromesCompletedNCT00324194Phase 1
• A Phase I Study of MGCD0103 Given Three-Times Weekly In Patients With Leukemia Or Myelodysplastic SyndromesCompletedNCT00324129Phase 1
• Phase I Study of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic PhaseWithdrawnNCT00324077Phase 1
• Study of MGCD0103 Given Three-Times Weekly in Patients With Advanced Solid Tumors or Non-Hodgkin's LymphomaCompletedNCT00323934Phase 1
• Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy.CompletedNCT00319969Phase 2
• A Phase IV Study of BMS-232632 in HIV+ Patients With Metabolic SyndromeTerminatedNCT00312754Phase 4
• Study of BMS-663513 in Patients With Advanced CancerTerminatedNCT00309023Phase 1/2
• Phase I Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis VulgarisCompletedNCT00306878Phase 1
• Study of BMS-582664 in Combination With Either FOLFIRI or FOLFOX for Gastrointestinal (GI) MalignanciesTerminatedNCT00300027Phase 1
• A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib MesylateCompletedNCT00298987Phase 2
• MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell LymphomaWithdrawnNCT00298467Phase 2
• A Dose-Escalation Study of MDX-1100 in Patients With Active Ulcerative ColitisCompletedNCT00295282Phase 1
• Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV MelanomaCompletedNCT00289640Phase 2
• A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV MelanomaCompletedNCT00289627Phase 2
• Phase II Randomized, Double-Blind, Placebo-Controlled Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis VulgarisCompletedNCT00287547Phase 2
• A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's DiseaseCompletedNCT00284804Phase 2
• Phase I/II Multiple-Dose LEA29Y vs CTLAG4Ig vs Placebo in Rheumatoid ArthritisCompletedNCT00279760Phase 1/2
• Vaccination Study of Abatacept (BMS-188667) for Normal Healthy VolunteersCompletedNCT00279734Phase 1
• A Study to Assess the Pharmacokinetics, Immunogenicity and Safety of Escalating Doses of BMS-188667 Given as a Single Intravenous Infusion to Patients With Psoriasis VulgarisCompletedNCT00277225Phase 1
• Comparability DE vs CD-CHO1CompletedNCT00277199Phase 1
• An Open Label Study in Patients With Advanced NSCLC With ABI-007(Abraxane) in Combination With CarboplatinCompletedNCT00274443Phase 2
• Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010)CompletedNCT00261365Phase 1/2
• Oral Direct Factor Xa-inhibitor Apixaban in Patients With Acute Symptomatic Deep-vein Thrombosis-The Botticelli DVT StudyCompletedNCT00252005Phase 2
• A Trial to Evaluate BMS-298585 as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic ControlCompletedNCT00246987Phase 3
• Efficacy and Safety of BMS-298585 Alone or in Combination With Pravastatin in Subjects With Mixed DyslipidemiaCompletedNCT00245388Phase 2/3
• Study of Recombinant Human Thrombin for Bleeding During SurgeryCompletedNCT00245336Phase 3
• Dose Ranging Study With LT, Monotherapy, PPARCompletedNCT00240383Phase 2/3
• A Study to Evaluate Combining Metformin With Muraglitazar or Pioglitazone in Type 2 DiabeticsCompletedNCT00240370Phase 3
• To Assess Compliance With a Once-daily Regimen of Lamivudine, Efavirenz and DidanosineCompletedNCT00207168Phase 4
• MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid TumorsCompletedNCT00207103Phase 1
• BMS-582664 in Combination With Erbitux in Patients With Advanced Gastrointestinal MalignanciesCompletedNCT00207051Phase 1
• A Phase I Study of BMS-275183 Given on a Daily Schedule in Patients With Advanced MalignanciesTerminatedNCT00207025Phase 1
• MAD Refractory: Solid Tumor QD w/o BreakCompletedNCT00207012Phase 1
• Clinical Trial Comparing Safety and Pharmacokinetics of Standard Antibiotic Therapy, Plus Aurexis® or Placebo, for Treatment of Staphylococcus Aureus Bacteremia (SAB)CompletedNCT00198302Phase 2
• Aurexis® in Cystic Fibrosis Subjects Chronically Colonized With Staphylococcus Aureus in Their LungsCompletedNCT00198289Phase 2
• A Phase I/II Study of Lenalidomide in Combination With Gemcitabine in Patients With Untreated Advanced Carcinoma of the PancreasTerminatedNCT00179751Phase 1/2
• A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid, CC-5013) in Subjects With Androgen Independent Prostate Cancer.TerminatedNCT00179738Phase 2
• Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal CarcinomaTerminatedNCT00179725Phase 1/2
• Study of Lenalidomide With Topotecan In Subjects With Advanced Ovarian and Primary Peritoneal CarcinomaCompletedNCT00179712Phase 1/2
• Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile Of Lenalidomide (Revlimid®, CC-5013) With Pemetrexed In Subjects With Advanced Non-Small Cell Lung CancerTerminatedNCT00179699Phase 1
• A Study to Evaluate the Single-Agent Lenalidomide in Subjects With Recurrent Non-Small-Cell Lung CancerCompletedNCT00179686Phase 2
• Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic ChemotherapyCompletedNCT00179608Phase 1
• A Phase I Study to Assess the Electrophysiologic Effects of BMS-394136 on the Atrium and Ventricle in Patients With Dual-Chamber Pacemakers or DefibrillatorsCompletedNCT00162448Phase 1
• Multiple Ascending Dose Study of BMS-582949 in Patients With Stable Rheumatoid Arthritis on the Methotrexate BackgroundCompletedNCT00162292Phase 1
• The Study of Abatacept in Combination With EtanerceptCompletedNCT00162279Phase 2
• Study of BMS-587101 in Patients With Moderate to Severe PsoriasisTerminatedNCT00162253Phase 2
• PPAR - Combination With MetforminCompletedNCT00162240Phase 3
• An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV InfectionNo longer availableNCT00162227
• Study of Dasatinib in Patients With Advanced Solid TumorsTerminatedNCT00162214Phase 1
• An Exploratory Study of Changes in Synovial Immune Responses Following BMS-188667 Therapy in Subjects With Active Rheumatoid Arthritis on Background DMARDs Who Have Failed Anti-TNF TherapyCompletedNCT00162201Phase 1
• An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection: CanadaNo longer availableNCT00162188
• PPAR-COMBO With SulfonylureaCompletedNCT00162175Phase 3
• ATV/Ritonavir Nevirapine Interaction (USPAC)CompletedNCT00162149Phase 1
• A Study of Prevalence of the I50L Mutation When ATV Treated Patients Fail the RegimenCompletedNCT00135447
• Effect of HIV Protease Inhibitor Drugs on Glucose and Insulin MetabolismCompletedNCT00135434Phase 1
• Study of BMS-562086 in the Treatment of Outpatients With Major Depressive DisorderCompletedNCT00135421Phase 1/2
• A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral BudesonideCompletedNCT00135408Phase 2
• A Phase IIIb Study Comparing Two Boosted Protease Inhibitor-based HAART Regimens in HIV-infected Patients Experiencing Their First Virologic Failure While Receiving an NNRTI-containing HAART RegimenCompletedNCT00135395Phase 3
• Study Switching HIV-1 Infected Patients With an Undetectable Viral Load on a First Protease Inhibitor-Based Regimen to an Efavirenz-Based RegimenCompletedNCT00135382Phase 3
• Switching HIV-1 Infected Subjects From a Highly Active Anti-Retroviral Treatment (HAART) Regimen Dosed Twice Daily or More Frequently to a Once-Daily RegimenCompletedNCT00135369Phase 3
• A Pilot Study of Atazanavir/Ritonavir/Efavirenz as a Nucleoside Sparing RegimenCompletedNCT00135343Phase 3
• Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid LeukemiaTerminatedNCT00126893Phase 1
• Study of HIV Patients With Undetectable Viral Load and Abnormal Lipids Switching to Atazanavir/RitonavirCompletedNCT00120393Phase 3
• Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Painful Lumbar RadiculopathyCompletedNCT00120120Phase 2/3
• DART I - A Phase IV Study of 3 Antiretroviral Medicines in Combination, in HIV Patients Who Have Not Been Previously Treated With Antiretroviral TherapyCompletedNCT00116415Not applicable
• Rollover Study for Zerit (Stavudine) ER Studies (-096, -099)CompletedNCT00116298Phase 3
• DART II - A Phase IV Study of 3 Antiretroviral Medicines in Combination, in HIV Patients Who Have Not Been Previously Treated With Antiretroviral TherapyCompletedNCT00116116Phase 4
• Safety and Efficacy of Veronate® Versus Placebo in Preventing Nosocomial Staphylococcal Sepsis in Premature InfantsCompletedNCT00113191Not applicable
• Irbesartan in the Treatment of Hypertensive Patients With Metabolic SyndromeCompletedNCT00110422Phase 4
• Study of Adriamycin Plus Cyclophosphamide Followed by Abraxane as Adjuvant Therapy for Patients With Breast CancerCompletedNCT00107094Phase 1
• Study of Muraglitazar Versus Pioglitazone in Type 2 DiabetesCompletedNCT00106808Phase 3
• A Research Study for Patients With Metastatic Renal Cell CarcinomaCompletedNCT00106613Phase 2
• A Research Study for Patients With Prostate CancerCompletedNCT00106418Phase 2
• Continuation Trial Evaluating the Tolerability and Activity of FK228 in Patients That Completed Prior Study With FK228CompletedNCT00106301Phase 2
• Study of KOS-862 (Epothilone D) in Metastatic Prostate CancerTerminatedNCT00104130Phase 2
• Oral Taxane in Combination With Pemetrexed (Alimta) in Patients With Recurrent Non-Small Cell Lung CancerCompletedNCT00103831Phase 1/2
• BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic LeukemiaCompletedNCT00103701Phase 1
• Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the UrotheliumCompletedNCT00101608Phase 2
• Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaCompletedNCT00101595Phase 2
• Study of BMS-275183 in Patients With Pre-treated Non-small Cell Lung CancerTerminatedNCT00099879Phase 2
• Phase I (PH I) Mad Refractory Solid Tumor StudyCompletedNCT00099606Phase 1
• BMS-562247 in Subjects Undergoing Elective Total Knee Replacement SurgeryCompletedNCT00097357Phase 2/3
• Entecavir for Subjects With Chronic Hepatitis B Infection: An Early Access ProgramNo longer availableNCT00096811
• Effect of the Atazanavir (ATV) 150L Mutation on Subsequent Treatment Response in HIV Infected SubjectsCompletedNCT00096746
• Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy for Patients With Moderate HypertensionCompletedNCT00095550Phase 3
• BMS-599626 in Patients With Advanced Solid MalignanciesCompletedNCT00095537Phase 1
• Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy as First Line Treatment for Severe HypertensionCompletedNCT00095394Phase 3

← Bristol-Myers Squibb overview and focus areas